Mylan Pharmaceuticals Initiates Nationwide Recall of Prasugrel Tablets Due to Dissolution Failure
Mylan Pharmaceuticals Inc. has initiated a voluntary Class II recall of Prasugrel Tablets, USP, 5 mg, distributed nationwide, due to failed dissolution specifications. This event, originating from their Morgantown, WV facility, signifies potential efficacy concerns for this critical antiplatelet drug. Procurement and supply chain leaders must assess immediate sourcing risks and monitor Mylan's corrective actions to mitigate future supply disruptions.
What the FDA Found: Summary of Violations
Mylan Pharmaceuticals Inc. has initiated a voluntary Class II recall, designated D-0280-2025, for specific lots of its Prasugrel Tablets, USP, 5 mg. The FDA identified the core issue as a failure to meet dissolution specifications, specifically exhibiting low dissolution results. For procurement directors and regulatory affairs heads, this is a critical quality attribute failure: the active pharmaceutical ingredient, Prasugrel Hydrochloride, may not release from the tablet at the intended rate or to the required extent. This can lead to reduced bioavailability, potentially rendering the medication sub-therapeutic and ineffective in preventing blood clots, a direct risk to patient safety for this essential antiplatelet therapy. The recall targets Prasugrel Tablets, USP, 5 mg, in 30-count bottles (NDC 0378-5185-93). Affected lots are 3211073, 3211074, and 3211075, expiring April 30, 2026. This US nationwide distribution means healthcare providers, pharmacies, and patients across the country are exposed to potentially compromised medication. Supply chain VPs must immediately review inventory, quarantine affected stock, and assess alternative sourcing. The voluntary recall, initiated by Mylan on February 25, 2025, underscores the firm's responsibility to address this critical quality defect promptly.
Facility Profile: Mylan's Morgantown Operations
The recalled Prasugrel Tablets were manufactured for Mylan Pharmaceuticals Inc. at their facility located at 1311 Pineview Drive, Morgantown, West Virginia, 26505, U.S.A. This site is a key component of Mylan's domestic manufacturing footprint, contributing to the supply of human prescription drugs within the United States. While specific details on the facility’s overall capacity or full product portfolio are not available, its role in producing a critical antiplatelet medication like Prasugrel highlights its importance to the US pharmaceutical supply chain. For business development executives and procurement teams, understanding the operational status and compliance record of manufacturing sites like Morgantown is paramount. A quality failure leading to a Class II recall signals potential vulnerabilities that could affect other products from this facility. The dissolution failure, while product-specific, could indicate broader quality system issues. This event necessitates a deeper dive into Mylan's quality management systems at the Morgantown site for any other molecules sourced from this location. Supply chain VPs should factor this incident into supplier risk profiles, recognizing that even established domestic facilities require continuous quality oversight.
Supply Chain Exposure: Impact on US Prasugrel Supply
The recall of Mylan Pharmaceuticals Inc.'s Prasugrel Tablets, USP, 5 mg, directly impacts the US nationwide supply chain for this critical antiplatelet medication. Prasugrel Hydrochloride is essential for patients undergoing procedures like percutaneous coronary intervention (PCI) to prevent thrombotic events. A Class II recall due to low dissolution results implies that a significant portion of the available supply may be ineffective, posing a direct risk to patient health outcomes. For procurement directors, this mandates an urgent review of current stock, identification of affected lots (3211073, 3211074, 3211075), and immediate quarantine across all distribution channels. The "US Nationwide" distribution confirms broad market exposure, affecting numerous downstream partners, hospitals, and retail pharmacies. Supply chain VPs must assess potential localized or regional shortages of Prasugrel and communicate proactively with their networks. Commercial implications extend beyond recall costs, including potential reputational damage for Mylan and increased pressure on remaining Prasugrel suppliers. Business development executives should note the competitive landscape shift, as this event may create opportunities for alternative manufacturers demonstrating robust quality and supply chain reliability. This situation underscores the need for agile supply chain management and robust contingency planning for critical therapies.
Alternative Suppliers: Navigating Prasugrel Sourcing Gaps
With Mylan Pharmaceuticals Inc.'s Prasugrel Tablets, USP, 5 mg, under a nationwide Class II recall, procurement directors face an immediate challenge in identifying and qualifying alternative sources for Prasugrel Hydrochloride. The available intelligence does not identify specific alternative suppliers for this molecule, highlighting the critical need for proactive supply chain diversification, especially for essential medicines. For regulatory affairs heads, qualifying a new supplier for a finished pharmaceutical product or API is a lengthy, complex process, involving extensive documentation, site audits, and potentially comparability studies to ensure quality and bioequivalence. Procurement teams must now initiate an accelerated search for manufacturers capable of supplying Prasugrel. This process typically involves identifying global candidates, assessing their regulatory compliance, conducting due diligence, and initiating formal qualification. Such timelines can range from several months to over a year. Supply chain VPs should prioritize suppliers with established FDA compliance and robust quality systems. The commercial implication is clear: companies with diversified sourcing for critical molecules like Prasugrel are better positioned to weather this disruption, while those reliant solely on Mylan will face significant operational and patient care challenges. This event serves as a stark reminder of the strategic imperative for a diverse and resilient supplier base.
The Broader Regulatory Environment and Mylan's Position
While the available intelligence does not detail a specific history of prior FDA Warning Letters, 483s, or Import Alerts directly linked to Mylan Pharmaceuticals Inc.'s Morgantown facility or Prasugrel production, this Class II recall for dissolution failure is a significant regulatory event. It signals a lapse in quality control that the FDA takes seriously, particularly for a medication with critical patient outcomes. For regulatory affairs heads, this incident places Mylan under heightened scrutiny, irrespective of past records. The FDA's Class II designation indicates that product use may cause temporary or medically reversible adverse health consequences, or where serious adverse health consequences are remote. This severity level still demands a robust and timely response. In the broader context, the pharmaceutical industry faces rigorous FDA oversight. Recent parallel events, such as Essential Wellness Pharma's progesterone injection failing sterility assurance and the FDA hearing on Amgen's Tavneos, highlight a consistently vigilant regulatory landscape. While these are unrelated to Mylan, they underscore the FDA's unwavering focus on manufacturing quality, product efficacy, and patient safety. For business development executives, this means the regulatory bar for market entry and sustained operations remains high; any quality lapse, even a voluntary recall, can have significant commercial repercussions and invite further regulatory attention.
Remediation Timeline and What Happens Next
Mylan Pharmaceuticals Inc. initiated the voluntary recall (D-0280-2025) for Prasugrel Tablets on February 25, 2025. The FDA's Center for Drug Evaluation and Research (CDER) classified the event on March 17, 2025, with the recall report dated March 26, 2025. The status remains "Ongoing," indicating Mylan is actively engaged in notifying customers, retrieving product, and investigating the root cause of the low dissolution results. For regulatory affairs heads, Mylan's immediate priority is ensuring the recall's effectiveness, preventing further distribution and use of affected lots (3211073, 3211074, 3211075). Beyond the immediate recall, Mylan is expected to conduct a comprehensive root cause analysis and implement robust Corrective and Preventive Actions (CAPA) to address manufacturing deficiencies. This will likely involve reviewing formulation, processes, quality control testing, and equipment at the Morgantown, WV facility. The FDA will closely monitor these efforts. Failure to implement effective CAPA could lead to further regulatory actions, including Warning Letters or increased inspections. Procurement directors and supply chain VPs should track Mylan's remediation progress, as the long-term reliability of this supplier for Prasugrel and other products depends on demonstrated sustainable quality improvements and regained regulatory confidence.